Floatz logo

LEVAMLODIPINE

Essential Hypertension

Chong Kun Dang PharmaceuticalSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Essential Hypertension cohort.

Asset / SponsorPhaseRating
AMLODIPINE
Yuhan Corporation
Phase 4BBB
Folic Acid
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4BB
Chlorthalidone
Yuhan Corporation
Phase 4BB
Micardis®
Yuhan Corporation
Phase 4B
Hydrochlorothiazide
Daiichi Sankyo
Phase 3B

View all 9 →

Same molecule, other indications

LEVAMLODIPINE is also rated in:

HypertensionDormant
BB
Indicative ·
68 / 100
View asset →
Metabolic SyndromeDormant
BB
Indicative ·
66 / 100
View asset →
Nonalcoholic Fatty Liver Disease (NAFLD)Dormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →